Dynavax Technologies Corporation

Dynavax Technologies — Investor Presentation (June 2018)

63 slides from Dynavax Technologies's investor presentation, Jun 5, 2018

  1. Slide 1: Analyst & Investor Presentation June 2018

    Analyst & Investor Presentation June 2018 Exhibit 99.3

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains "forward-looking" statements, including statements regarding the conduct of clinical trials of SD-101, including results from the Phase 1b/2 trial, planned optimal dosage for the Phase 3 trial, and potential value of SD-101 across multiple tumor t

  3. Slide 3: Presenters

    Presenters COMPANY Eddie Gray – Chief Executive Officer Robert L. Coffman, PhD – Chief Scientific Officer Rob Janssen, MD – Chief Medical Officer Jean Chang – VP, Cancer Strategy and Business Development Michael Ostrach – Chief Financial Officer (available for Q&A) Erick Gamelin – VP, Clinical Devel

  4. Slide 4: Agenda

    Agenda TLR9 Agonists for Cancer Immunotherapy – Mechanisms Robert L. Coffman Resistance to PD-1 Blockade Due to Lack of Pre-existing Antitumor immunity Toni Ribas Clinical Development – Ph1b/2 Melanoma Data and Additional Programs Rob Janssen Maximizing Value of Dynavax’s TLR9 Agonist Portfolio in t

  5. Slide 5: Deep and Growing Clinical Pipeline

    Deep and Growing Clinical Pipeline RESEARCH PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL VACCINE IMMUNO-ONCOLOGY SD-101 + Pembrolizumab* for Melanoma SD-101 + Pembrolizumab* for Head and Neck SCC Inhaled DV281 for NSCLC Additional Programs (including TLR 7/8 agonists) IMMUNE-MEDIATED AZD1419 (Asth

  6. Slide 6: Robert L. Coffman, PhD

    Robert L. Coffman, PhD

  7. Slide 7: SD-101: Optimized TLR9 Agonist for Cancer Immunotherapy

    SD-101: Optimized TLR9 Agonist for Cancer Immunotherapy SD-101 Synthetic DNA oligonucleotide with TLR9-reactive CpG motifs Optimized for two key dendritic cell activation pathways TLR9 activation of dendritic cells complements other major classes of immuno-oncology agents. NF-kB IRF-7 Nucleus IFNa I

  8. Slide 8: SD-101: Optimized TLR9 Agonist for Cancer Immunotherapy

    SD-101: Optimized TLR9 Agonist for Cancer Immunotherapy Triggering dual pathways provides more potent response Activates dendritic cells to become efficient antigen-presenting cells Induces type 1 IFN, leading to development of cytotoxic T cells (CTL) SD-101 CTL NF-kB IRF-7 Nucleus IFNa IL-12 Dendri

  9. Slide 9: SD-101: Optimized TLR9 Agonist for Cancer Immunotherapy

    SD-101: Optimized TLR9 Agonist for Cancer Immunotherapy Inside tumor, CTL recognize and kill tumor cells, releasing more tumor antigens Establishes self-amplifying process leading to control or elimination of malignant cells SD-101 CTL NF-kB IRF-7 Nucleus IFNa IL-12 Dendritic Cell Late Endosome Earl

  10. Slide 10: Actions of Intratumoral SD-101 in Cancer Immunotherapy

    Actions of Intratumoral SD-101 in Cancer Immunotherapy Tumor IFN DC T cell Dendritic cells take up antigens from dying tumor cells and migrate to the lymph nodes SD-101 Tumor antigens Lymph node DC Dying tumor Tumor-specific T cells activated by DC and IFN in lymph node Blood vessel CTL CTL CTL SD-1

  11. Slide 11: Actions of Intratumoral SD-101 in Cancer Immunotherapy

    Actions of Intratumoral SD-101 in Cancer Immunotherapy Tumor IFN DC T cell Dendritic cells take up antigens from dying tumor cells and migrate to the lymph nodes SD-101 Lymph node DC Dying tumor Tumor-specific T cells activated by DC and IFN in lymph node Blood vessel CTL CTL CTL SD-101 induces IFN

  12. Slide 12: Actions of Intratumoral SD-101 in Cancer Immunotherapy

    Actions of Intratumoral SD-101 in Cancer Immunotherapy Tumor IFN DC T cell Dendritic cells take up antigens from dying tumor cells and migrate to the lymph nodes SD-101 Lymph node DC Dying tumor Tumor-specific T cells activated by DC and IFN in lymph node Blood vessel CTL CTL CTL SD-101 induces IFN

  13. Slide 13: Actions of Intratumoral SD-101 in Cancer Immunotherapy

    Actions of Intratumoral SD-101 in Cancer Immunotherapy Tumor IFN DC T cell Dendritic cells take up antigens from dying tumor cells and migrate to the lymph nodes SD-101 Lymph node DC Dying tumor Tumor-specific T cells activated by DC and IFN in lymph node Blood vessel CTL CTL CTL SD-101 induces IFN

  14. Slide 14: SD-101 + Local Radiation in Lymphoma Leads to Abscopal Response

    SD-101 + Local Radiation in Lymphoma Leads to Abscopal Response in Many Patients 1 -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 2 3 4 5 6 7 8 9 10 11 12 13 14 Subject 15 16 17 18 19 20 21 22 23 24 25 26 27 28 1 mg 2 mg 4 mg 8 mg Cohort Percent Change From Baseline (%) Best objective res

  15. Slide 15: Actions of Intratumoral SD-101 in Cancer Immunotherapy

    Actions of Intratumoral SD-101 in Cancer Immunotherapy Tumor IFN DC T cell SD-101 Lymph node DC Dying tumor Blood vessel CTL CTL CTL Tumor IFN IFN Chemokines (CXCL9, 10) NK cell CTL T cell PD-L1 PD1 Anti-PD1 Tumor PD-1/PD-L1 blockade will enhance killing by CTL

  16. Slide 16: Combination with Anti-PD-1 Increases Anti-tumor Response

    Combination with Anti-PD-1 Increases Anti-tumor Response Tumor IFN DC T cell SD-101 Lymph node DC Dying tumor Blood vessel CTL CTL CTL Tumor IFN IFN Chemokines (CXCL9, 10) NK cell CTL T cell PD-L1 PD1 Anti-PD1 Tumor PD-1/PD-L1 blockade will enhance killing by CTL Anti-PD-1 will also increase both th

  17. Slide 17: Preclinical Studies in Mice Support Combining SD-101 With Checkpoint Inhibitors

    Preclinical Studies in Mice Provide Support for Combining SD-101 With Checkpoint Inhibitors In preclinical studies, addition of intratumoral SD-101 reverses tumor escape from anti-PD-1 therapy and leads to durable immune-mediated rejection of CT26 tumors Untreated Anti-PD-1+SD-101 Anti-PD-1 Untreate

  18. Slide 18: SD-101 and Anti-PD-1 Synergize to Increase Functional CD8+ T Cells

    SD-101 and Anti-PD-1 Synergize to Increase Functional CD8+ T Cells in the Injected Tumor Stimulated CD3+CD8+ T cells IFN-γ TNF-α The combination of SD-101 and anti-PD-1 leads to substantial increases in both the numbers and functionality of the tumor-infiltrating CD8+ T cells Control Anti-PD1 non-re

  19. Slide 19: Biomarkers Show Increased Immune Activity with Combination

    Biomarkers Show Increased Immune Activity with Combination Cytotoxic T and NK Cells Increase in Melanoma Patients Treated with Intratumoral SD-101 + Pembrolizumab

  20. Slide 20: Toni Ribas, MD, PhD

    Toni Ribas, MD, PhD

  21. Slide 21: Resistance to PD-1 blockade due to lack of pre-existing antitumor immunity

    Resistance to PD-1 blockade due to lack of pre-existing antitumor immunity Antoni Ribas, M.D., Ph.D. Professor of Medicine, Surgery, Molecular and Medical Pharmacology Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center (JCCC) Director, Parker Institute for Cancer Immunotherapy (

  22. Slide 22: Management of Cancer in the Anti-PD-1/L1 Era

    Management of Cancer in the Anti-PD-1/L1 Era Features likely for response Features unlikely for response Upfront combination therapy Durable response Mixed response or delayed progression . . . . . . . . Delayed combined therapy

  23. Slide 23: The Cancer Immunogram

    Tumor foreignness Mutational load General immune status Lymphocyte count Immune cell infiltration Intratumoral T cells Absence of Checkpoints PD-L1 Absence of soluble inhibitors IL6->CRP/ESR Tumor sensitivity to immune effectors MHC expression IFN-g sensitivity Absence of inhibitory tumor metabolism

  24. Slide 24: Anti-PD-1/L1 Approved Indications and Suspected Mechanism of Action

    Anti-PD-1/L1 Approved Indications and Suspected Mechanism of Action Group Indication ORR Agents approved* Main driver of response High response rate Hodgkin’s disease 87% Nivolumab, pembrolizumab PDJ amplicon Desmoplastic melanoma 70% Nivolumab, pembrolizumab Mutations from chronic sun exposure Merk

  25. Slide 25: Anti-PD-1/L1 Approved Indications and Suspected Mechanism of Action

    Anti-PD-1/L1 Approved Indications and Suspected Mechanism of Action Group Indication ORR Agents approved* Main driver of response High response rate Hodgkin’s disease 87% Nivolumab, pembrolizumab PDJ amplicon Desmoplastic melanoma 70% Nivolumab, pembrolizumab Mutations from chronic sun exposure Merk

  26. Slide 26: Inhibiting PD-1-mediated Adaptive Immune Resistance

    Inhibiting PD-1-mediated Adaptive Immune Resistance TCR MHC Melanoma cell or tumor macrophage PD-1 PD-L1 IFN-g Anti-PD-1 Anti-PD-L1 Pardoll, NRC 2012 Taube et al. STM 2012 Tumeh et al. Nature 2014

  27. Slide 27: Inhibiting PD-1-mediated Adaptive Immune Resistance

    Inhibiting PD-1-mediated Adaptive Immune Resistance Tumeh et al. Nature 2014 TCR MHC Melanoma cell or tumor macrophage PD-1 PD-L1 IFN-g Anti-PD-1 Anti-PD-L1

  28. Slide 28: Delayed Response to PD-1 Blockade after Transient Progression

    Baseline Day +27 Day +92 Day +130 Delayed Response to PD-1 Blockade after Transient Progression Tumeh et al. Nature 2014

  29. Slide 29: What Differentiates Anti-PD-1-responsive from Non-responding Melanomas?

    Pembrolizumab Keynote 001 trial. Central radiology review by RECIST v1.1 What Differentiates Anti-PD-1-responsive from Non-responding Melanomas? Ribas et al. JAMA 2016 Ayers et al, JCI 2017

  30. Slide 30: PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance

    Melanoma cell or tumor macrophage PD-L1 Hypothesis formulated based on quantitative IHC analyses of 46 cases from UCLA Response Progression CD8 PD-1 PD-L1 Patient #1 Patient #2 PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance Adapted from Tumeh et al. Nature 2014 TCR MHC Mela

  31. Slide 31: Reversing T Cell Exclusion with Intra-tumoral Therapies

    Reversing T Cell Exclusion with Intra-tumoral Therapies Anti-PD-1/anti-PD-L1 IT injection oncolytic virus TLR agonist, MDA5 agonist STING agonist May bring rare antitumor T cells into tumors and improve responds to anti-PD-1/L1 therapy + Anti-PD-1/anti-PD-L1

  32. Slide 32: Intra-tumoral T-VEC Plus Systemic Pembrolizumab Induces High Response Rates

    Intra-tumoral T-VEC (oncolytic virus) Plus Systemic Pembrolizumab Induces High Response Rates by Increases in Tumor CD8 Infiltration T-VEC T-VEC+ pembro –100 –75 –50 –25 0 25 50 75 100 Stage IV M1c (N = 8) Stage IV M1b (N = 4) Stage IV M1a (N = 2) Stage IIIC (N = 6) Stage IIIB (N = 1) N = 21 Percent

  33. Slide 33: Intra-tumoral TLR9 Agonists Plus Systemic Checkpoint Blockade

    Intra-tumoral TLR9 Agonists Plus Systemic Checkpoint Blockade Anti-PD-1/L1 Naïve SD101 + pembrolizumab Progressing on prior anti-PD-1/L1 CMP-001 + pembrolizumab IMO-2125 + ipilimumab [ 240 ]

  34. Slide 34: Conclusions

    Conclusions Inhibiting adaptive immune resistance is the mechanistic basis of the antitumor activity of PD-1 blockade therapies Patients without a pre-existing tumor antigen-specific T cell infiltrate inducing reactive PD-L1 expression are unlikely to respond to PD-1 blockade therapy Inducing intrat

  35. Slide 35: Rob Janssen, MD

    Rob Janssen, MD

  36. Slide 36: SYNERGY-001 (MEL-01) Phase 1b/2 Study

    SYNERGY-001 (MEL-01) Phase 1b/2 study of the combination of SD-101 and pembrolizumab in advanced melanoma and head and neck squamous cell cancer OBJECTIVES: Evaluate the safety of the combination Evaluate the preliminary efficacy of the combination Establish the dose of SD-101 for the Phase 3 trial

  37. Slide 37: Understanding Dose Selection

    Understanding Dose Selection SD-101 Mechanism of Action is to stimulate the immune system to respond to specific antigens Efficacy may be most informative – Looking for “sweet-spot”/the Goldilocks dose. Not too hot, not too cold! Blood PK not informative – Primary mechanism is local in the tumor and

  38. Slide 38: Study Design

    Study Design Data cutoff – May 9, 2018 Patients Stage IIIc, Stage IV metastatic melanoma* ECOG performance status of 0 or 1 At least one injectable site Response by RECIST v1.1 Prior anti-PD-1 or anti-PD-1 naive Phase 1b Dose Escalation** Phase 2 Expansion SD-101 2 mg i.t. + Pembrolizumab 200 mg i.v

  39. Slide 39: Response Rate Higher in the Lower Dose Group

    Response Rate Higher in the 2 mg Dose Group * mITT excludes patients on study with no Day 64 scan yet. † Patients discontinued prior to first scan: ≤ 2 mg—clinical progression (n=1), irAE (n=1); 8 mg—clinical progression (n=2), AE/death (n=1); irAE (n=3), withdrew consent (n=1). ** Patients on study

  40. Slide 40: Subgroup Analyses Support Lower Dose

    Subgroup Analyses Support 2 mg Dose CI = confidence interval; ECOG = Eastern Cooperative Oncology Group performance status; LDH = lactate dehydrogenase; ORR = overall response rate; RR = risk ratio; ULN = upper limit of normal.

  41. Slide 41: Responses in Patients with PD-L1 Negative or Positive Tumors

    2mg 8mg Responses in Patients with PD-L1 Negative or Positive Tumors Reponses seen in patients with negative and positive PD-L1 expression at baseline 80% (8 out of 10) of PD-LI negative patients responded with 2mg of SD-101

  42. Slide 42: Best Percent Change in Target Lesions

    Best Percent Change in Target Lesions

  43. Slide 43: Tumor Shrinkage Seen in Injected and Non-injected Lesions

    Tumor Shrinkage Seen in Injected and Non-injected Lesions

  44. Slide 44: Durability and Time on Study by Dose Group

    6 month PFS rate = 76% Median PFS (months) = not reached Median DOR (months) = 4.7+ (not reached) Median Follow up (months) = 6.0 6 month PFS rate = 41% Median PFS (months) = 4.2 Median DOR (months) = 2.1+ (not reached) Median Follow up (months) = 4.9 Durability and Time on Study by Dose Group 2 mg

  45. Slide 45: Increase in Infiltrating CD4 and CD8 Lymphocytes in the Tumor

    Increase in Infiltrating CD4 and CD8 Lymphocytes in the Tumor Red = CD4 T cells; Cyan = CD8 T cells; Yellow = Ki67; Green = S100; Dark blue = DAPI. Subject 110404 was devoid of CD4 T cells but not CD8 T cells at screening. Subject 110401 appeared to be devoid of CD4 and CD8 T cells at screening. Scr

  46. Slide 46: Combination of SD-101 and Pembrolizumab is Well Tolerated

    Combination of SD-101 and Pembrolizumab is Well Tolerated Event ≤2 mg/lesion (N=37) 8 mg/lesion (N = 39) Total (N=76) n (%) n (%) n (%) Any Treatment-related AE 28 (76) 36 (92) 64 (84) Grade 3-4 8 (22) 14 (36) 22 (29) Chills 3 (8) 1 (3) 4 (5) Myalgia 6 (16) 1 (3) 7 (9) Injection-site pain 2 (5) 0 2

  47. Slide 47: Encouraging Early Data in Anti-PD-1/L1 Naïve HNSCC Patients

    Encouraging Early Data in Anti-PD-1/L1 Naïve HNSCC Patients (AACR 2018) *Includes all patients who had a tumor assessment and patients who discontinued the study prior to a scan. Cut-off date, 27 March 2018. Among patients who had a scan, ORR = 38%. †Two patients had clinical disease progression, in

  48. Slide 48: SYNERGY-001 Conclusions

    SYNERGY-001 Conclusions Efficacy - addition of SD-101 to pembrolizumab appears to improve pembrolizumab responses ≤ 2 mg of SD-101 per lesion induced a higher and more durable response rate than pembrolizumab with 8 mg of SD-101 ≤ 2 mg dose better than 8 mg dose in all disease stages Tumor shrinkage

  49. Slide 49: Proceeding to Phase 3

    Proceeding to Phase 3 Continue to enroll patients in Phase 2 to receive 2 mg SD-101: Melanoma: anti-PD-1/L1 experienced HNSCC: anti-PD-1/L1 naïve and experienced Proposed Phase 3 study design: Randomized, double-blind, placebo controlled 2 mg of SD-101 in 1 to 4 lesions Unresectable or metastatic me

  50. Slide 50: Jean Chang

    Jean Chang

  51. Slide 51: Evolution of Cancer Therapy Landscape

    Evolution of Cancer Therapy Landscape Combinations Checkpoint IO Targeted Chemotherapy Kills all rapidly dividing cells Toxicities Response rates limited Specific genes or proteins in cancer cells Rapid responses Better tolerated Responses not durable Activate immune system against the tumor by inhi

  52. Slide 52: A Range of Combinations Will Emerge Over Time

    A Range of Combinations Will Emerge Over Time Immune system is intricate Multiple and redundant feedback mechanisms Mechanisms maintain immune system balance Patients are heterogeneous Prior therapies Tumor microenvironment Tumor mutational burden

  53. Slide 53: Four Classes of Agents Appear Well Suited to Complement PD-1 Blockade

    Four Classes of Agents Appear Particularly Well Suited to Complement PD-1 Blockade Increasing appreciation in IO field that stimulation of innate immune system is required to optimally exploit T cell activation Other agents that inhibit or block a checkpoint Activate or expand T cells Agents that al

  54. Slide 54: TLR9 Agonists + Anti-PD1: A Promising Combination

    TLR9 Agonists + Anti-PD1: A Promising Combination Characteristics of a successful combination treatment Robust response Durable disease control Not reliant on predictive biomarkers Minimal additive toxicity burden for patients Implications Earlier use may maximize outcomes, e.g. neoadjuvant setting

  55. Slide 55: SD-101 + Anti-PD1: Development in Melanoma

    SD-101+ Anti-PD1: Development in Melanoma Establish SD-101 + pembrolizumab as core combination Advance SD-101+ pembrolizumab combination into earlier treatment settings Unresectable or metastatic melanoma naïve population Phase 3 SD-101 + pembrolizumab Unresectable or metastatic melanoma refractory/

  56. Slide 56: Leveraging Shift in Melanoma Treatment towards Neoadjuvant Setting

    SD-101 + Anti-PD1: Leveraging Shift in Melanoma Treatment towards Neoadjuvant Setting Checkpoint blockade, anti-PD1 in particular, is moving into the neoadjuvant setting (earlier is better) Pembrolizumab is showing early efficacy SD-101 fits well within this shift TLR9 agonists can improve responses

  57. Slide 57: Application to Additional Indications in Neoadjuvant Setting

    TLR9 Agonists + Anti-PD1: Application to Additional Indications in Neoadjuvant Setting Criteria for cancer selection Stage at diagnosis Amenable to series of injections or inhalation Evidence of anti-PD1 activity Potential to raise the bar for outcomes Clinical response Pathologic complete/major res

  58. Slide 58: Strong Basis for Additional Combinations

    Building on the Strength of Dynavax’s SD-101 + Pembrolizumab Data: Strong Basis for Additional Combinations T cells Checkpoint inhibitors or Activators anti-PD1 anti-ICOS* anti-OX-40* … … Epigenetic modulators* LD Chemo* … … … TLR9 SD-101 or DV281 Innate Immunity Antigen Presentation/Prime T-cells T

  59. Slide 59: Dynavax TLR9 Agonists Fill Gap in Pharma Combination Pipelines

    Dynavax TLR9 Agonists Fill Gap in Pharma Combination Therapy Pipelines Pharmaceutical companies continue to build combination optionality across multiple mechanisms Considerable opportunity exists within our class of agents Dynavax clinical programs can fill Pharma’s pipeline gap, creating opportuni

  60. Slide 60: Use Partnering to Make TLR9 Agonists Broadly Available

    Use Partnering to Make TLR9 Agonists Broadly Available and Integral to Combination Therapy Goals for collaborations and partnerships Maximize breadth across tumor types Maximize combination use Doublets or triplets with anti-PD1 treatments Doublets with other T cell agonists, particularly in tumors

  61. Slide 61: Developing TLR-mediated Immune Stimulation in Multiple Cancer Applications

    Dynavax: Developing TLR-mediated Immune Stimulation in Multiple Cancer Applications Pre-clinical assessment of novel combinations Cancer Vaccine DV230 Ficoll for liver indications NSCLC Neoadjuvant NSCLC Lung mets Phase 3 MEL naive Phase 2 MEL anti-PD1 refractory/resistant HNSCC tx-naïve HNSCC anti-

  62. Slide 62: Eddie Gray

    Eddie Gray

  63. Slide 63: Concluding Remarks

    Concluding Remarks TLR9 agonist technology has demonstrated encouraging potential in immuno-oncology as a combination agent Growing immuno-oncology database validates our ongoing studies and expansion of our program Positioning ourselves to take advantage of anti-PD-1 therapy shift into neoadjuvant

Dynavax Technologies — Investor Presentation (June 2018) on 6ix